Effectiveness and Safety of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer: A Multi-center Real-world Retrospective Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Patients aged over 18 years old.
• Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
• Plan to receive or has received Sacituzumab Govitecan monotherapy
• Available medical history.
Locations
Other Locations
China
Fudan University Shanghai Cancer Center
RECRUITING
Shanghai
Contact Information
Primary
Biyun Wang, Professor
pro_wangbiyun@163.com
+8613701748410
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2025-04-01
Participants
Target number of participants: 150
Treatments
Sacituzumab Govitecan
Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
Related Therapeutic Areas
Sponsors
Leads: Fudan University